Mannose Binding Lectin (MBL / MBP)

Immunology

---

Description

MBL is a member of the Collectin family, which are proteins characterised by the presence of collagen-like and lectin-binding domains. MBL is produced in the liver and secreted into the blood, where it constitutes an important element in innate immune defense [1]. MBL shares functional features in common with C1q, IgM and IgG. It is associated with a serine protease (MASP); MBL associated serine protease is activated when MBL binds to microbial carbohydrate surfaces and in turn activates the lectin pathway of the complement cascade. MBL deficiencies are associated with defects of opsonisation and an increased risk of infection when the adaptive immune system is immature (in early childhood) [2] or has been suppressed (e.g. after organ transplantation or during cancer chemotherapy) [3], and with a poorer prognosis in cystic fibrosis. Low concentration of MBL in serum or plasma is common and does not necessarily imply the existence of any disease [2]. The results must be interpreted alongside the patient's clinical features.

---

Indications

Recurrent infections in childhood or during chemotherapy.

---

Sample Type

2mL Serum (Gel 5mL Yellow tube). Requests from outside Sheffield: Transport at ambient temperature via Royal Mail or Courier.

---

Reference Range

Normal Values are: 0.7 - 6.0 mg/L. Reference ranges established by manufacturer and verified in-house.

---

Turnaround Time

Within 10 days

---

Testing Frequency

Weekly

---

External Notes

Discuss with Immunologist.

---

References

Thiel S, Frederiksen PD and Jensenius JC. Clinical manisfestations of mannan-binding lectin deficiency. Mol Immun. 2006. 43:86-96. [Ref 1]
Ruskamp JM, et al. Mannose binding lectin and upper respiratory tract infections in children and adolescents.Arch. Otolaryngol. Head Neck Surgery. 2006. 132:482-486. [Ref 2]
Peterslund NA, et al. Association between deficiency of mannose-binding lectin and severe infections after chemotherapy. Lancet. 2001. 358:637-638. [Ref 3]

---

Please note: the above information is subject to change and we endeavour to keep this website up to date wherever necessary.